218631-48-2

Usage

Uses

Used in Pharmaceutical Research:
1-(4-METHOXYPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOLE-5-CARBOXYLIC ACID is used as a building block for the synthesis of new drug candidates due to its unique structure and functional groups, which may enhance the biological activity of the resulting compounds.
Used in Chemical Synthesis:
In the chemical industry, 1-(4-METHOXYPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOLE-5-CARBOXYLIC ACID is used as a precursor for the preparation of other chemical compounds with desired properties, taking advantage of its trifluoromethyl and methoxyphenyl moieties to improve the pharmacological profile of the synthesized compounds.
Used in Drug Discovery and Development:
1-(4-METHOXYPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOLE-5-CARBOXYLIC ACID is also of interest for further study in drug discovery and development, as the presence of the trifluoromethyl and methoxyphenyl groups could potentially enhance its pharmacological profile, making it a valuable asset in creating new therapeutic agents.

Upstream product

• 503614-63-9 5-(furan-2-yl)-1-(4-methoxyphenyl )-3-(trifluoromethyl )-1H-pyrazole 
• 104-94-9 4-methoxy-aniline 
• 326-90-9 4,4,4-trifluoro-1-(2-furanyl)-1,3-butanedione 
• 218632-10-1 5-methyl-1-(4-methoxyphenyl)-3-trifluoromethyl-1H-pyrazole 
• 19501-58-7 4-methoxyphenylhydrazine hydrochloride 
• 367-57-7 1,1,1-Trifluoro-2,4-pentanedione 
• 218631-47-1 5-hydroxymethyl-1-(4-methoxyphenyl)-3-trifluoromethyl-1H-pyrazole 
• 637318-19-5 acetic acid 2-(4-methoxy-phenyl)-5-trifluoromethyl-2H-pyrazol-3-ylmethyl ester 

Downstream Products

• 503613-32-9 methyl 2-[2-fluoro-4-(2-oxo-1(2H)-pyridinyl)phenyl]-3-[1-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]-3-oxopropanoate 
• 1026090-28-7 2-(4-methoxy-phenyl)-5-trifluoromethyl-2H-pyrazole-3-carboxylic acid (2'-tert-butylsulfamoyl-3-fluoro-biphenyl-4-yl)-amide 
• 218631-49-3 1-(4-methoxyphenyl)-3-trifluoromethyl-1H-pyrazole-5-(N-(2'-N-tert-butylaminosulfonyl-[1,1']-biphen-4-yl))carboxamide 
• 1026554-09-5 2-(4-methoxy-phenyl)-5-trifluoromethyl-2H-pyrazole-3-carboxylic acid [5-(2-tert-butylsulfamoyl-phenyl)-pyridin-2-yl]-amide 
• 218632-09-8 2-(4-methoxy-phenyl)-5-trifluoromethyl-2H-pyrazole-3-carbonyl chloride 

Relevant academic research and scientific papers

LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS

The present application describes lactam-containing compounds and derivatives thereof of Formula I: P4—P-M-M4??I or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.

HUMAN PLASMA KALLIKREIN INHIBITORS

Disclosed are compounds of formula (I), as described herein, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.

Discovery of 1-(2-Aminomethylphenyl)-3-trifluoromethyl-N-[3-fluoro-2′ -(aminosulfonyl)[1,1′-biphenyl)]-4-yl]-1H-pyrazole-5-carboxyamide (DPC602), a Potent, Selective, and Orally Bioavailable Factor Xa Inhibitor

Factor Xa, a serine protease, is at the critical juncture between the intrinsic and extrinsic pathways of the coagulation cascade. Inhibition of factor Xa has the potential to provide effective treatment for both venous and arterial thrombosis. We recentl

INHIBITORS OF FACTOR XA WITH A NEUTRAL P1 SPECIFICITY GROUP

The present application describes inhibitors of factor Xa with a neutral P1 specificity group of formula I: STR1 or pharmaceutically acceptable salt forms thereof, wherein R and E may be groups such as methoxy and halo.